Unlock stock picks and a broker-level newsfeed that powers Wall Street.

ASX - Delayed Quote AUD

Radiopharm Theranostics Limited (RAD.AX)

Compare
0.0210
0.0000
(0.00%)
As of 11:51:11 AM GMT+10. Market Open.
Currency in AUD All numbers in thousands
Breakdown
TTM
6/30/2024
6/30/2023
6/30/2022
Total Revenue
299.2280
299.2280
292.3590
8.8310
Gross Profit
299.2280
299.2280
292.3590
8.8310
Operating Expense
36,920.0800
36,920.0800
34,800.4440
19,925.1830
Operating Income
-36,620.8520
-36,620.8520
-34,508.0850
-19,916.3520
Net Non Operating Interest Income Expense
-592.4040
-592.4040
58.9440
-9,349.7390
Other Income Expense
-10,639.4990
-10,639.4990
-124.0480
-1,028.4910
Pretax Income
-47,852.7550
-47,852.7550
-34,573.1890
-30,294.5820
Tax Provision
96.3640
96.3640
38.0050
44.3970
Net Income Common Stockholders
-47,949.1190
-47,949.1190
-34,611.1940
-30,338.9790
Basic EPS
-0.12
-0.12
-0.11
-0.15
Diluted EPS
-0.12
-0.12
-0.11
-0.15
Basic Average Shares
386,460.1370
386,460.1370
323,816.5390
198,514.2960
Diluted Average Shares
386,460.1370
386,460.1370
323,816.5390
198,514.2960
Net Income from Continuing & Discontinued Operation
-47,949.1190
-47,949.1190
-34,611.1940
-30,338.9790
Normalized Income
-46,913.8946
-46,913.8946
-32,441.1940
-30,338.9790
Interest Income
50.4840
50.4840
145.0350
--
Interest Expense
642.8880
642.8880
86.0910
9,349.7390
Net Interest Income
-592.4040
-592.4040
58.9440
-9,349.7390
EBIT
-47,209.8670
-47,209.8670
-34,487.0980
-20,944.8430
EBITDA
-44,083.5810
-44,083.5810
-31,190.5660
-17,963.3590
Reconciled Depreciation
3,126.2860
3,126.2860
3,296.5320
2,981.4840
Net Income from Continuing Operation Net Minority Interest
-47,949.1190
-47,949.1190
-34,611.1940
-30,338.9790
Total Unusual Items Excluding Goodwill
-1,478.8920
-1,478.8920
-3,100
--
Total Unusual Items
-1,478.8920
-1,478.8920
-3,100
--
Normalized EBITDA
-42,604.6890
-42,604.6890
-28,090.5660
-17,963.3590
Tax Rate for Calcs
0.0003
0.0003
0.0003
0.0003
Tax Effect of Unusual Items
-443.6676
-443.6676
-930
--
6/30/2022 - 11/24/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers